270 related articles for article (PubMed ID: 23865835)
1. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
Zaja F; Federico M; Vitolo U; Zinzani PL
Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
[TBL] [Abstract][Full Text] [Related]
2. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
3. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
5. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
6. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapy for the treatment of mantle cell lymphoma.
Rajguru S; Kahl BS
J Natl Compr Canc Netw; 2014 Sep; 12(9):1311-8; quiz 1318. PubMed ID: 25190697
[TBL] [Abstract][Full Text] [Related]
8. Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):185-7. PubMed ID: 10721785
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
10. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
13. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS
J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871
[TBL] [Abstract][Full Text] [Related]
14. Evolving treatment strategies in mantle cell lymphoma.
Edwin NC; Kahl B
Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
[TBL] [Abstract][Full Text] [Related]
15. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
16. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
Njue A; Colosia A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):1-12.e7. PubMed ID: 25052050
[TBL] [Abstract][Full Text] [Related]
19. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Coiffier B
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
